Innoprot in vitro fibrosis models enable the study of fibrosis-related parameters in response to drug treatment such as; TGF-β/Smad3, fibronectin expression, alpha-SMA expression or collagen expression. Additionally, our TGF-β induced fibrosis assays enable the identification of potential inhibitors; such as the specific TGF-β type I receptor (Alk5) inhibitor, known as SB525334.
Our Astrocytosis assay enables the study of fibrosis-related parameters on TGF-β1 induced Human primary astrocytes. Astrocytosis assay from Innoprot allows the evaluation of therapeutic compounds in this disease area by measuring several biomarkers; including Fibronectin, ASMA and also Collagen via high content analysis. Astrocytosis is a common neurocellular manifestation of brain pathology in individuals with…
Cardiac Fibrosis Assay from Innoprot enables monitoring TGF-β/Smad signaling activation on Human Cardiac Fibroblasts. Immortalized primary Human Cardiac Fibroblasts stimulated with TGF-β1 demonstrate a clear concentration-dependent increase in Smad Binding Elements (SBE) expression; while increasing the TGF-β1 stimuli showes no effect of on the number of nuclei, indicative of no cytotoxic events. TGF-β trigger is…
Renal Fibrosis Assay from Innoprot enables the study of fibrosis-related parameters on TGF-β induced Renal Tubular Epithelial Cells. Human Renal Tubular Epithelial Cells stimulated with TGF-β1 demonstrate a clear concentration-dependent increase in αSMA levels; while increasing the TGF-β1 stimuli showes no effect of on the number of nuclei, indicative of no cytotoxic events. TGF-β trigger…